ViiV Healthcare Launches Phase 3 Trial of Ultra Long-Acting HIV Injectable with 4-Month Dosing, Challenging Gilead
Need for Ultra Long-Acting Treatment and Initiation of Phase 3 Trial
ViiV Healthcare has commenced patient enrollment in a Phase 3 trial (NCT07650916) evaluating an ultra long-acting (ULA) injectable combination of cabotegravir and rilpivirine. This study aims to extend the dosing interval of its existing long-acting (LA) injectable, Cabenuva, from 1-2 months to a significantly longer period of 4 months (16 weeks). By reducing the burden of daily medication or frequent clinic visits, this strategy seeks to improve adherence and reduce treatment failure rates. This approach holds significant clinical value in alleviating the daily challenges faced by patients with chronic diseases and maximizing their quality of life.
Detailed Design and Control Group of the NCT07650916 Trial
This clinical trial will involve 564 adult and adolescent patients (12 years and older) who have achieved virological suppression with antiretroviral therapy (ART). Researchers will focus on demonstrating non-inferiority in efficacy and safety of the ULA injectable compared to the existing standard LA injectable. Specifically, the primary endpoint is the proportion of patients with HIV-RNA levels below 50 copies/mL at Month 11, as assessed using the FDA snapshot algorithm. This head-to-head comparison with Cabenuva is a strategic move to facilitate a natural product lifecycle transition and prevent market cannibalization.
Shift in HIV Treatment Paradigm and Threat from Competitor Gilead
The global HIV treatment market, currently valued at $37 billion to $41 billion, is rapidly shifting towards long-acting injectables for improved convenience. Gilead Sciences, the market leader, has already launched Sunlenca (lenacapavir), a 6-month injectable, for multi-drug resistant patients. ViiV Healthcare likely recognized that its existing 1-2 month regimen would be insufficient to counter Gilead's ultra long-acting injectable strategy. Therefore, the success of this ULA formulation is crucial for ViiV Healthcare to maintain a strong competitive position in the HIV maintenance therapy market, which is expected to exceed $50 billion.
Regulatory Approval Potential and Future Market Outlook
ViiV Healthcare's parent company, GSK, aims to initiate this trial in June 2026 and complete it by September 2029. Given that the trial is based on cabotegravir and rilpivirine, which have already demonstrated safety and efficacy, the clinical risk is expected to be relatively low. If approved by regulatory authorities, the ULA formulation, with its reduced dosing frequency of only 3 times per year, will significantly improve patient convenience. This is expected to contribute significantly to ViiV Healthcare's revenue diversification and life cycle management of existing products facing patent expiration.
ViiV Healthcare's Phase 3 trial of cabotegravir and rilpivirine ultra long-acting (ULA) injectable aims to maximize patient convenience by reducing the annual dosing frequency to 3 times, offering significant long-term benefits. This is considered a key countermeasure against Gilead Sciences' 6-month injectable, Sunlenca, in the $37 billion to $41 billion global HIV treatment market, where Gilead seeks to maintain its dominant position. The success of this trial, involving 564 participants, represents an excellent development strategy by extending the dosing interval of a proven treatment by 4 months, thereby minimizing clinical risk while maximizing commercial value. In the short term, it is important to monitor the sales performance of the existing long-acting injectable, Cabenuva, until the trial is completed in 2029. In the medium to long term, the approval of the ULA formulation will be a key driver in reshaping market share within the HIV market. From the perspective of industry professionals and researchers, the validation of the ultra long-acting formulation technology for a 2-drug regimen is expected to accelerate the transition to injectable treatments for a wider range of chronic diseases.
Source: ClinicalTrials.gov (api_ct)